服用吸入式類固醇或長效支氣管擴張劑的氣喘病患在癌症上的風險: 以台灣全人口基礎的前瞻式世代研究

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：32

、訪客IP：18.190.239.122

姓名

黃煦凱(Hsu-Kai Huang) 查詢紙本館藏

畢業系所

資訊工程學系

論文名稱

服用吸入式類固醇或長效支氣管擴張劑的氣喘病患在癌症上的風險: 以台灣全人口基礎的前瞻式世代研究
(Risk of cancers among asthmatic patients with inhaled corticosteroids or long-acting beta2-agonists usage: A population-based prospective cohort study in Taiwan)

相關論文

★ 應用嵌入式系統於呼吸肌肉群訓練儀之系統開發	★ 勃起障礙與缺血性心臟病的雙向研究: 以台灣全人口基礎的世代研究
★ 基質輔助雷射脫附飛行時間式串聯質譜儀微生物抗藥性資料視覺化工具	★ 使用穿戴式裝置分析心律變異及偵測心律不整之應用程式
★ 建立一個自動化分析系統用來分析任何兩種疾病之間的關聯性透過世代研究設計以及使用承保抽樣歸人檔	★ 青光眼病患併發糖尿病,使用Metformin及Sulfonylurea治療得到中風之風險:以台灣人口為基礎的觀察性研究
★ 利用組成識別和序列及空間特性構成之預測系統來針對蛋白質交互作用上的特殊區段點位進行分析及預測辨識	★ 新聞語意特徵擷取流程設計與股價變化關聯性分析
★ 藥物與疾病關聯性自動化分析平台設計與實作	★ 建立財務報告自動分析系統進行股價預測
★ 建立一個分析疾病與癌症關聯性的自動化系統	★ 基於慣性感測器虛擬鍵盤之設計與實作
★ 一個醫療照護監測系統之實作	★ 應用手機開發手握球握力及相關資料之量測
★ 利用關聯分析全面性的搜索癌症關聯疾病	★ 全面性尋找類風濕性關節炎之關聯疾病

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

[檢視]

[下載]

本電子論文使用權限為同意立即開放。
已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中)

氣喘是一個常見的肺部疾病，具有慢性發炎、氣流阻塞和支氣管過度反應的特性，此外，慢性發炎已經被指出與致癌的關係密切。對氣喘病患而言，吸入式類固醇是最有效的抗發炎藥物而且被建議為第一線治療，當病患服用低劑量的吸入式類固醇控制不良時，則必須增加吸入式類固醇的劑量或者再加入長效支氣管擴張劑控制藥物(建議)。因此，我們從全民健康保險研究資料庫抓取20歲以上的新發氣喘病患，再來排除一些會影響我們研究的病患，然後評估常態性服用吸入式類固醇或長效支氣管擴張劑在癌症風險上的影響。最後，我們觀察到常態性服用吸入式類固醇(沒有服用長效支氣管擴張劑)的使用者，若平均每天吸入式類固醇劑量小於或等於2000微克，對整體癌症以及肺癌和肝癌有保護的效果，若超過2000微克則對前列腺癌有保護的效果。然而，常態性服用吸入式類固醇和長效支氣管擴張劑的使用者，若平均每天吸入式類固醇劑量小於或等於2000微克，會增加肺癌風險，若超過2000微克則會增加整體癌症以及口腔癌和皮膚癌的風險。另外，常態性服用長效支氣管擴張劑(沒有服用吸入式類固醇)的使用者，我們沒有發現長效支氣管擴張劑的使用與整體癌症風險之間的關聯。

摘要(英)

Asthma is a common pulmonary disorder, which is characterized by chronic inflammation, airflow obstruction and bronchial hyperresponsiveness. Furthermore, the close relationship between chronic inflammation and carcinogenesis has been reported. Currently, inhaled corticosteroid (ICS) is the most effective anti-inflammatory drug for patients with asthma and recommended as first-line therapy. When patients do not control asthma well with the low-dose ICS, they have to either increase the dosage of ICS or add the long-acting ß-agonist (LABA) controller medication (recommended). Thus, we select ≥20 years newly asthmatic patients from National Health Insurance Research Database (NHIRD), exclude some patients who affect our study and evaluate the effects of regular use of ICS or LABA on the cancers risk. Finally, we observe that ICS have protective effects on overall, lung and liver cancer when taking ≦2000 mcg/day as well as on prostate cancer when taking >2000 mcg/day among ICS only regular users. However, ICS/LABA regular users significantly increase risk of lung cancer when taking ≦2000 mcg/day ICS dosage as well as of overall, oral and skin cancer when taking >2000 mcg/day ICS dosage. In addition, we do not find the association between LABA use and overall cancer risk among LABA only regular users.

關鍵字(中)

★ 氣喘
★ 吸入式類固醇
★ 長效支氣管擴張劑
★ 癌症
★ 台灣
★ 世代研究

關鍵字(英)

★ asthma
★ inhaled corticosteroids
★ long-acting beta2-agonists
★ cancer
★ Taiwan
★ cohort study

論文目次

摘要........................................................i
ABSTRACT...................................................ii
誌謝......................................................iii
Table of Contents..........................................iv
List of Figures............................................vi
List of Tables............................................vii
Chapter 1 Introduction......................................1
1.1 Background...........................................1
1.2 Motivation...........................................2
1.3 Research Goal........................................3
Chapter 2 Related Works.....................................4
2.1 Lung Cancer and Laryngeal Cancer.....................4
2.2 Bladder Cancer.......................................5
2.3 Prostate Cancer......................................5
2.4 Non-melanoma Skin Cancer.............................5
2.5 Breast Cancer........................................6
Chapter 3 Materials and Methods.............................7
3.1 Data Source..........................................7
3.2 Drugs Regular User Definition........................7
3.3 Study Design.........................................7
3.4 Inhaled Corticosteroid Exposure.....................10
3.5 Confounding Factors.................................10
3.6 Statistical Analysis................................10
Chapter 4 Results..........................................12
4.1 Demographic Characteristics.........................12
4.2 Incidence Rate of Cancer............................14
4.3 Risk of Cancers.....................................18
4.4 Kaplan-Meier Cancers-Free Curves....................21
Chapter 5 Discussion.......................................25
Chapter 6 Conclusion.......................................31
References.................................................32

參考文獻

1.National Asthma Education and Prevention Program (National
Heart Lung and Blood Institute). Expert Panel Report 3:
Guidelines for the Diagnosis and Management of Asthma:
Full Report 2007. U.S. Department of Health and Human
Services, National Institutes of Health, National Heart,
Lung, and Blood Institute.
2.Global Initiative for Asthma (GINA). Global Strategy for
Asthma Management and Prevention(Updated 2012).
3.Jan IS, Chou WH, Wang JD, Kuo SH. Prevalence of and major
risk factors for adult bronchial asthma in Taipei city. J
Formos Med Assoc 2004; 103: p.259-63.
4.Wu WF, Wan KS, Wang SJ, Yang W, Liu WL. Prevalence,
severity, and time trends of allergic conditions in 6-to-7-
year-old schoolchildren in Taipei. J Investig Allergol
Clin Immunol 2011; 21(7): p.556-62.
5.Ji J, Shu X, Li X, Sundquist K, Sundquist J, Hemminki K.
Cancer risk in hospitalised asthma patients. Br J Cancer
2009; 100: p.829–33.
6.Hwang CY, Chen YJ, Lin MW, Chen TJ, Chu SY, Chen CC, Lee
DD, Chang YT, Wang WJ, Liu HN. Cancer risk in patients
with allergic rhinitis, asthma and atopic dermatitis: a
nationwide cohort study in Taiwan. Int J Cancer 2012;
130(5): p.1160–7.
7.Lisa M. Coussens, Zena Werb. Inflammation and cancer.
Nature 2002; 420: p.860-867.
8.Alberto Mantovani, Paola Allavena, Antonio Sica, Frances
Balkwill. Cancer-related inflammation. Nature 2008; 454:
p.436–444.
9.van den Berge M, ten Hacken NH, Kerstjens HAM, Postma DS.
Management of asthma with ICS and LABAs: different
treatment strategies. Clin Med Ther 2009; 1: p.77-93.
10.Sadatsafavi M, Lynd L, Marra C, Bedouch P, Fitzgerald M.
Comparative outcomes of leukotriene receptor antagonists
and long-acting beta-agonists as add-on therapy in
asthmatic patients: a population-based study. J Allergy
Clin Immunol 2013; 132: p.63-9.
11.Tee AK, Koh MS, Gibson PG, et al. Long-acting beta2-
agonists versus theophylline for maintenance treatment of
asthma. Cochrane Database Syst Rev 2007; 18(3):CD001281.
12.Hsiao JL, Chen FS, Wang YL, Chen CY. The prescription
trend analysis of the use of inhalers in Taiwanese
asthmatics. Formosa Journal of Clinical Pharmacy 2012;
20(2): p.141-155.
13.Nargues A. Weir, Stewart J. Levine. Achieving symptom
control in patients with moderate asthma. Clinical
Medicine Insights: Circulatory, Respiratory and Pulmonary
Medicine 2012; 6: p.1-11.
14.Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au
DH. Inhaled corticosteroids and risk of lung cancer among
patients with COPD. Am J Respir Crit Care Med 2007; 175:
p.712-719.
15.Victor A. Kiri, Leonardo M. Fabbri, Kourtney J. Davis,
Joan B. Soriano. Inhaled corticosteroids and risk of lung
cancer among COPD patients who quit smoking. Respiratory
Medicine 2009; 103: p.85-90.
16.Lee CH, Hyun MK, Jang EJ, Lee NR, Kim K, Yim JJ. Inhaled
corticosteroid useand risks of lung cancer and laryngeal
cancer. Respir Med 2013; 107: p.1222-33.
17.Dietrich K, Schned A, Fortuny J, et al. Glucocorticoid
therapy and risk of bladder cancer. Br J Cancer 2009;
101: p.1316–20.
18.Severi G, Baglietto L, Muller DC, et al. Asthma, asthma
medications, and prostate cancer risk. Cancer Epidemiol
Biomarkers Prev 2010; 19: p.2318–24.
19.Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer
SK, Nierenberg DW. Non-melanoma skin cancers and
glucocorticoid therapy. Br J Cancer 2001; 85: p.683–6.
20.Sorensen GV, Cronin-Fenton DP, Sorensen HT, Ulrichsen SP,
Pedersen L, Lash TL. Use of glucocorticoids and risk of
breast cancer: a Danish population-based case-control
study. Breast Cancer Res 2012; 14: R21.
21.Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM.
The Salmeterol Multicenter Asthma Research Trial: a
comparison of usual pharmacotherapy for asthma or usual
pharmacotherapy plus salmeterol. Chest 2006; 129:
p.15–26.
22.Drazen JM, O’Byrne PM. Risks of long-acting
beta-agonists in achieving asthma control. N Engl J Med
2009; 360: p.1671-2.
23.Chowdhury BA, Dal Pan G. The FDA and safe use of
long-acting beta-agonists in the treatment of asthma. N
Engl J Med 2010; 362: p.1169-71.
24.Wells KE, Peterson EL, Ahmedani BK, Severson RK, Gleason-
Comstock J, Williams LK. The relationship between
combination inhaled corticosteroid and long-acting
beta-agonist use and severe asthma exacerbations in a
diverse population. J Allergy Clin Immunol 2012; 129:
p.1274–1279.
25.Ducharme FM, Chronin N, Greenstone I, Lasserson TJ.
Addition of long-acting beta2-agonists to inhaled
steroids versus higher dose inhaled steroids in adults
and children with persistent asthma. Cochrane Database
Syst Rev 2010; (4):CD005533
26.Kelly HW. Comparison of inhaled corticosteroids. Ann
Pharmacother 1998; 32: p.220-232.
27.Walser T, Cui X, Yanagawa J, et al. Smoking and lung
cancer: the role of inflammation. Proc Am Thorac Soc
2008; 5(8): p.811–815.
28.Yasushi Rino, Kazuo Tarao. Anti-Inflammatory Drugs Reduce
the Risk of Hepatocellular Carcinoma Development. ISRN
Oncology 2011; 2011.
29.Sahasrabuddhe V V, Gunja MZ, Graubard BI, Trabert B,
Schwartz LM, Park Y, et al. Nonsteroidal
anti-inflammatory drug use, chronic liver disease, and
hepatocellular carcinoma. J Natl Cancer Inst 2012; 104:
p.1808-1814.
30.Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM,
Nelson WG. Anti-inflammatory drugs, antioxidants, and
prostate cancer prevention. Curr Opin Pharmacol 2009; 9:
p.419–26.
31.Mahmud SM, Franco EL, Turner D et al. Use of
non-steroidal anti-inflammatory drugs and prostate cancer
risk: a population-based nested case-control study. PLoS
One 2011; 6(1): e16412.
32.Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ. Use of
aspirin, but not other non-steroidal anti-inflammatory
drugs is associated with decreased prostate cancer risk
at the population level. Eur J Cancer 2013; 49: p.938-945.
33.Spies CM, Strehl C, van der Goes MC, Bijlsma JW,
Buttgereit F. Glucocorticoids. Best Pract Res Clin
Rheumatol 2011; 25: p.891-900.
34.Jensen P, Hansen S, Möller B et al. Skin cancer in kidney
and heart transplant recipients and different long-term
immunosuppressive therapy regimens. J Am Acad Dermatol
1999; 40: p.177–86.
35.De Hertog SA, Wensveen CA, Bastiaens MT, et al. Relation
between smoking and skin cancer. J Clin Oncol 2001; 19:
p.231-8.
36.Rollison DE, Iannacone MR, Messina JL, Glass LF, Giuliano
AR, Roetzheim RG, et al. Case-control study of smoking
and non-melanoma skin cancer. Cancer Causes Control 2012;
23: p.245-54.
37.P. A. Jayalekshmi, P. Gangadharan, S. Akiba, R. R. K.
Nair, M. Tsuji, and B. Rajan. Tobacco chewing and female
oral cavity cancer risk in Karunagappally cohort, India.
The British Journal of Cancer 2009; 100(5): p.848–852.
38.SV Glavey, N Keane, M Power, AW O′Regan. Posterior
Pharyngeal Candidiasis in the Absence of Clinically Overt
Oral Involvement: A Cross-Sectional Study. Lung 2013;
191(6): p.663-668.
39.Sanjaya PR, Gokul S, Gururaj PB, Raju R. Candida in oral
pre-cancer and oral cancer. Med Hypotheses 2011; 77:
p.1125–1128.
40.Dahl R. Systemic side effects of inhaled corticosteroids
in patients with asthma. Respir Med 2006; 100(8):
p.1307-17.

指導教授

洪炯宗(Jorng-Tzong Horng)

審核日期

2014-7-25

推文